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Purpose: In this prospective study, the effects of fresh frozen plasma (FFP) includ-
ed in pump priming for congenital heart surgery in infants and children on post-by-
pass coagulation profiles were evaluated. Materials and Methods: Either 20% al-
bumin (50-100 mL) or FFP (1-2 units) was added to pump priming for patients 
randomly allocated into control or treatment groups, respectively. Hematologic as-
says, including functional fibrinogen level, and rotational thromboelastometry 
(ROTEM®) were measured before skin incision (baseline), after weaning from car-
diopulmonary bypass (CPB) and heparin reversal, and at 24 hours (h) in the inten-
sive care unit (ICU). Results: All the baseline measurements were comparable be-
tween the control and treatment groups of infants and children. After heparin 
reversal, however, significantly higher fibrinogen levels and less reduced ROTEM 
parameters, which reflect clot formation and firmness, were demonstrated in the 
treatment groups of infants and children. At 24 h in the ICU, hematologic assays 
and ROTEM measurements were comparable between the control and treatment 
groups of infants and children. Transfusion requirements, excluding FFP in pump 
prime, and postoperative bleeding were comparable between the control and treat-
ment groups of infants and children. Conclusion: Although clinical benefits were 
not clearly found, the inclusion of FFP in pump priming for congenital heart sur-
gery in infants and children was shown to improve the hemodilution-related hemo-
static dysfunction immediately after weaning from CPB and heparin reversal.
Key Words:   Congenital heart disease, cardiopulmonary bypass, blood coagula-
tion disorder, fresh frozen plasma
INTRODUCTION
Infants and children undergoing cardiac surgery with cardiopulmonary bypass 
(CPB) frequently present with post-bypass coagulation abnormalities that are pri-
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randomly allocated into either control or treatment groups, 
which received 20% human albumin or FFP in pump prim-
ing, respectively. Coagulopathy after CPB is associated 
with patient age;12 therefore, all patients were divided into 
infants (younger than 12 months) or children (older than 1 
year) and the control and treatment groups within each age 
population were compared as follows: infants control vs. 
infants treatment, and children control vs. children treat-
ment. To assess an individual surgical risk, an Aristotle Ba-
sic Complexity score was assigned to all patients, based on 
the main operation designated by the surgeon.14 With the 
exception of perfusionists, anesthesiologists, surgeons, and 
personnel working in the ICU were all blinded to the desig-
nated group of a patient. 
Anesthesia was induced with intravenous ketamine (1-2 
mg/kg) with vecuronium (0.1-0.2 mg/kg) for muscle relax-
ation. Maintenance of anesthesia was achieved with a con-
tinuous infusion of ketamine (20-25 µg/kg/min), supple-
mented by intermittent inhalation of sevoflurane (<1.2 
vol%) in oxygen and air before the initiation of CPB. For 
maintenance of anesthesia during CPB, fentanyl (20-30 µg/
kg) and vecuronium (0.1-0.2 mg/kg) were given at the be-
ginning of CPB and at the initiation of rewarming. Before 
cannulation of CPB, systemic anticoagulation was accom-
plished with IV heparin (300 units/kg of body weight). 
During CPB, additional doses of heparin were given to 
maintain an activated clotting time (ACT) of >450 sec. For 
heparin reversal, an initial dose of protamine was calculated 
to equal the pre-bypass dose of heparin. Additional doses of 
protamine were given until ACT returned to the baseline 
values. 
The pump priming solution, the volume of which was 
calculated on the basis of body weight, included crystalloid 
fluid (Plasma solution A®, CJ Pharma, Seoul, Korea) and 
packed red blood cells (PRBC) to obtain a predictive hema-
tocrit value of 30% after dilution. To maintain the colloid 
oncotic pressure, either 20% human albumin (50-100 mL) 
or FFP (1-2 units) was added to pump priming for patients 
randomly allocated to control or treatment groups, respec-
tively. Volume differences between 20% human albumin 
and FFP were eliminated with the crystalloid component to 
reach the calculated volume of pump priming. Medications 
in pump priming included 20% mannitol (5 mL/kg of body 
weight), heparin (1 unit) and 8.4% NaHCO3 (0.4 mL) per 1 
mL of priming volume, CaCl2 (60-90 mg per unit of stored 
PRBC), and 5% dextrose-in-water (10 mL/kg of body 
weight when the patient weight was <30 kg). The CPB cir-
marily attributed to hemodilution from a larger volume of 
pump priming relative to patient’s blood volume.1-3 De-
creased concentration of coagulation factors, particularly fi-
brinogen, is known to be a major cause of post-bypass co-
agulation abnormalities.4,5 Fresh whole blood, collected 48 
hours (h) before surgery, has an adequate concentration of 
coagulation factors, including fibrinogen, can provide ade-
quate volume replacement and is an example of blood 
product that has been considered ideal for pump priming.6 
However, reports evaluating the hemostatic benefit of the 
fresh-collected blood products for pump priming in neo-
nates or infants undergoing CPB are divergent.7,8 Further-
more, fresh-collected blood products are not readily avail-
able at most institutions. Given that the most convenient 
alternative source of fibrinogen is fresh frozen plasma 
(FFP), the use of FFP in pump priming in infants weighing 
<8-10 kg was previously shown to increase fibrinogen lev-
els after CPB.9,10 While neonates and small infants are most 
vulnerable to post-bypass coagulation derangement,11-13 it is 
necessary to evaluate the effects of FFP in pump prime for 
pediatric cardiac surgery on post-bypass hemostasis in a 
wide variety of patients, including older children or those 
undergoing repeat sternotomy. Additionally, it is important 
to use not only laboratory measurements, including fibrino-
gen level, but also functional evaluations of rotational 
thromboelastometry (ROTEM®, TEM Innovations, Mu-
nich, Germany). The aim of this prospective investigation 
is to evaluate the effects of FFP in pump priming for cardi-
ac surgery in infants and children on the post-bypass coagu-
lation profiles. 
MATERIALS AND METHODS
　　　
After obtaining approval from local ethics committee and 
written consent from parents, 123 pediatric patients, aged 1 
month to 16 years who were scheduled for elective cardiac 
surgery with CPB were recruited for this investigation. Ex-
clusion criteria were as follows: neonate (<1 month of age), 
previously diagnosed coagulation disorders of non-cardio-
vascular origin, and any metabolic disorder leading to ab-
normalities in plasma protein profiles. Additionally, if a pa-
tient was transferred to the intensive care unit (ICU) with 
the chest open for hemodynamic instability, or required sur-
gical re-exploration for postoperative bleeding within 24 h 
after initial surgery, that patient was also excluded from the 
analysis. Using a sealed envelope method, patients were 
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Statistical analysis
Based on previous investigations, power analyses suggested 
that the inclusion of >20 patients per group would enable de-
tection of a >30 mL/kg difference in mean chest tube drain-
age during 24 h ICU stay between the control and treatment 
groups with a chance of 80% (α=0.05, β=0.2). Categorical 
variables are presented as the numbers of patients (percent), 
and a χ2-test was used for statistical analysis. Continuous 
variables are presented mean±SD or median (interquartile 
range), and statistically evaluated with Student’s t-tests or 
Mann-Whitney U tests, as appropriate. A p-value of <0.05 
was considered statistically significant. 
 
RESULTS
 
A total of 123 patients were initially recruited, but one in 
the infant treatment group and one patient in the children 
control group were excluded as they required delayed ster-
nal closure for hemodynamic stability. In total, 121 infants 
and children were finally included for analysis. Patient char-
acteristics, and surgical and bypass data were comparable 
between the control and treatment groups of infants and 
children (Table 1). 
Diagnosis and corresponding surgery for infants are pre-
sented in Table 2-1, showing no differences between the 
control and treatment groups. In children, there were no dif-
ferences for surgical procedures performed between the 
control and treatment groups (Table 2-2). 
Preoperatively, Hb/Hct, platelet count, functional fibrino-
gen level, PT and aPTT were all comparable between the 
control and treatment groups of infants and children. After 
protamine administration, Hb/Hct were significantly higher 
in the infants treatment group than those in the infants con-
trol group, however, comparable between the children con-
trol and children treatment groups. Functional fibrinogen 
levels were greater in the treatment groups of infants and 
children after heparin reversal. Thereafter, there were no 
differences in Hb/Hct, platelet count, fibrinogen level, PT 
and aPTT between the control and treatment groups of in-
fants and children at 24 h in the ICU (Table 3-1). The ACT 
data measured before skin incision and after heparin rever-
sal are presented in Table 3-2, showing no significant dif-
ferences between the control and treatment groups of in-
fants and children, except for significantly longer ACT 
measurement after protamine administration in the infant 
control compared to the infant treatment group. 
cuits contained a hard-shell venous reservoir and a hollow-
fiber membrane oxygenator (Capiox Baby Rx®, Terumo, To-
kyo, Japan), which were adapted to patient size, an arterial 
filter, and a roller pump. Non-pulsatile blood flow was 
maintained at 2.0-2.4 mL/min/m2 with mild hypothermia of 
28-32°C measured rectally. The target temperature of hypo-
thermia was determined by the surgeon according to the 
planned surgical procedure. Cold, intermittent blood cardio-
plegia, prepared during CPB, was used for myocardial pro-
tection. The α-stat strategy was applied throughout the CPB 
period. To maintain the hematocrit >28% during CPB peri-
od, additional PRBC was given to the CPB circuit and/or 
ultrafiltration was performed at the discretion of the assigned 
perfusionist. In principle, modified ultrafiltration (MUF) in 
arteriovenous fashion was done for 5-10 min after weaning 
from CPB in every patient. However, in 33 patients (27%), 
MUF could not be done because clinical conditions didn’t 
permit. Additional transfusion of blood products after hepa-
rin reversal was at the discretion of the anesthesiologist and 
intensivist who were responsible for patient care in the op-
erating theater and ICU, respectively.
Study protocol
Laboratory tests, including hemoglobin concentration and 
hematocrit (Hb/Hct), platelet count, functional fibrinogen 
level, prothrombin time (PT) and activated partial thrombo-
plastin time (aPTT) were done as routine preoperative work-
ups. Measurements of arterial blood gas (ABG), ACT and 
rotational thromboelastogram (ROTEM®, TEM Innova-
tions, Munich, Germany) were performed before skin inci-
sion as baseline values. ROTEM measurements included 
INTEM, EXTEM and FIBTEM for analysis of intrinsic 
and extrinsic coagulation pathways and fibrinogen activity, 
respectively. Except for FIBTEM, which contains ampli-
tude at 10 min after CT (A10) and maximal clot firmness 
(MCF) only, all ROTEM measurements have the following 
parameters in common: clotting time (CT), A10, clot for-
mation time (CFT), α angle, and MCF. After weaning from 
CPB and heparin reversal, Hb/Hct, platelet count, function-
al fibrinogen level, ABG, ACT and ROTEM measurements 
were repeated. Surgical blood loss and transfusion require-
ments during the surgery were calculated and recorded. 
During ICU stay, chest tube drainage and transfusion re-
quirements were recorded for the initial 24 h. At the first 
postoperative day, laboratory tests, including Hb/Hct, platelet 
count, functional fibrinogen level, PT, aPTT, and ROTEM 
measurements were performed for follow-up. 
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dren control and children treatment groups after protamine 
administration, as well as at 24 h in the ICU. For EXTEM 
measurements, slightly shorter CFT and greater α were ob-
served in the children treatment group after protamine ad-
ministration, then no differences were shown between the 
children control and children treatment groups at 24 h in 
the ICU. For FIBTEM measurements, A10 and MCF were 
greater in the children treatment group after heparin rever-
sal. MCF was still greater in the children treatment group at 
24 h in the ICU, but statistical significance was marginal 
(p=0.048) (Table 4-2). 
ROTEM measurements performed before skin incision 
were comparable between the infants control and infants 
treatment groups. After heparin reversal, however, shorter 
CFT and greater α for INTEM and EXTEM, and greater 
A10 and MCF for all three ROTEM measurements were 
shown in the infants treatment group. However, at 24 h in 
the ICU, there were no differences in ROTEM values be-
tween the infants control and infants treatment groups (Ta-
ble 4-1). In children, baseline ROTEM values did not differ 
between the control and treatment groups. INTEM mea-
surements were shown to be comparable between the chil-
Table 1. Patient Characteristics and Surgical and Bypass Data for Infants and Children
Infants Children
Control (n=28) Treatment (n=26) p value Control (n=33) Treatment (n=34) p value
Sex (M/F) 15/13 8/18 0.107 18/15 19/15 1.000
Female sex    13 (46.4)   18 (69.2) 0.107    15 (45.5%)    15 (44.1%) 1.000
Age (month)   2.6 (1.5, 3.7)  3.6 (2.1, 6.8) 0.062    68 (45.3, 166)  121 (42.2, 177.9) 0.695
Body weight (kg)   4.7 (4.1, 6.2)  5.7 (4.4, 7.3) 0.166 20.3 (14.4, 38) 28.3 (14, 50) 0.437
BSA (m2)   0.3 (0.2, 0.3)  0.3 (0.2, 0.4) 0.231   0.8 (0.6, 1.3)      1 (0.6, 1.5) 0.405
ABC score      6 (6, 8.8)  6.8 (6, 9.1) 0.221   7.8 (6.8, 9)   7.5 (6.4, 8.9) 0.281
Cyanotic disease      3 (10.7)     6 (23.1) 0.286      7 (21.2)      3 (8.8) 0.186
Repeat sternotomy      3 (10.7)     3 (11.5) 1.000    22 (66.7)    23 (67.6) 1.000
Bypass time (min) 96.5 (66, 117.8) 115 (85, 165.3) 0.101    98 (71.5, 134)  110 (86, 169.5) 0.172
ACC time (min) 66.5 (44, 87.3)   80 (52.8, 114.8) 0.337    49 (27.5, 92)    63 (6.8, 116.3) 0.597
BSA, body surface area; ABC score, Aristotle Basic Complexity score; ACC time, aortic cross-clamp time. 
Data are presented as numbers of patients (percent) or median (interquartile range). 
Table 2-1. Diagnoses and Corresponding Surgeries for Infants
Diagnosis Surgery Control Treatment
VSD Repair 15 (53.6)   8 (30.8)
ASD Repair 1 (3.9)
VSD+ASD Repair   3 (10.8)   3 (11.6)
ECD Total correction 2 (7.2)
DORV+VSD Repair 2 (7.2) 1 (3.9)
DORV+VSD+PS Repair+RVOT enlargement 2 (7.7)
DORV+VSD+PS, s/p central shunt Repair+RVOT enlargement 1 (3.6)
TOF Total correction   3 (11.6)
TOF+ECD Total correction+valve repair 1 (3.9)
MS, s/p VSD+CoA repair Mitral valvular repair 1 (3.6)
PS, s/p central shunt Glenn’s shunt 1 (3.9)
PA+VSD Central shunt+MPA repair 1 (3.9)
PA+VSD, s/p BT shunt, Rt. Rastelli’s op+VSD repair 1 (3.6) 1 (3.9)
PA+VSD, s/p central shunt Glenn’s shunt 1 (3.9)
CoA+VSD End-to-end anastomosis+repair 1 (3.6) 1 (3.9)
Cor triatriatum+ASD Repair 1 (3.6) 1 (3.9)
TAPVR Total correction 1 (3.6)
Pulmonary venous stenosis Repair 1 (3.9)
VSD, ventricular septal defect; ASD, atrial septal defect; ECD, endocardial cushion defect; DORV, double outlet right ventricle; PS, pulmonary stenosis; TOF, 
tetralogy of Fallot; MS, mitral stenosis; CoA, coarctation of aorta; BT shunt, Blalock-Taussig shunt; PA, pulmonary atresia; TAPVR, total anomalous pulmo-
nary venous return; RVOT, right ventricular outflow tract; MPA, main pulmonary artery.   
Data are presented as numbers of patients (percent).
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prime, however, the amount of transfusion after protamine 
administration was comparable between the infants control 
and infants treatment groups (Table 5-1). 
In children, there were no differences in additional PRBC 
during CPB and PRBC transfusion after heparin reversal be-
tween the control and treatment groups. But FFP transfusion 
was significantly greater in the children control group after 
protamine administration. Transfusion of platelets and autol-
ogous salvaged blood did not differ between the children 
control and children treatment groups. Total amount of intra-
operative transfusion requirements were also comparable 
between the children control and children treatment groups. 
Total transfusion requirements without FFP in pump prim-
ing were greater in the children control group but the differ-
ence was not statistically significant (p=0.06) (Table 5-1). 
During 24 h of ICU stay, there were no differences found 
in the total amount of transfusion requirements, as well as 
in the transfusion requirements of individual blood prod-
ucts between the control and treatment groups of infants 
and children. Chest tube drainage for 24 h in the ICU was 
also comparable between the control and treatment groups 
of infants and children (Table 5-2). 
Perioperatively, there were no significant differences in 
the ABG measurements between the control and treatment 
groups of infants and children (data not shown). 
DISCUSSION
Inclusion of FFP in pump priming for congenital heart sur-
gery was shown to significantly lessen hemodilution-induced 
reductions in fibrinogen level immediately after heparin re-
versal, resulting in improvements in thromboelastometry pa-
rameters reflecting clot formation and firmness in infants 
and children. These beneficial effects of FFP in pump prim-
ing, however, were not sustained until 24 h in the ICU, and 
any clinical benefits of transfusion requirements and/or 
postoperative bleeding were not clearly demonstrated. 
Post-CPB coagulopathy can be described as “dilution-
al”,1-3 and hypofibrinogenemia has been demonstrated to be 
a major cause.4,5 In this study, platelet count and functional 
fibrinogen level were all reduced immediately after heparin 
reversal in the control and treatment groups of infants and 
children even though hemodilution was considered to be 
well-compensated with modified ultrafiltration, evidenced 
by comparable Hb/Hct measurements pre- and post-CPB. 
In the treatment groups, however, fibrinogen levels were 
It is reasonable that the amount of FFP added into the 
pump prime was significantly greater in the treatment groups 
of infants and children. No differences were found in the 
amount of PRBC in pump priming between the control and 
treatment groups of infants and children. 
The amount of additional PRBC given to the CPB circuit 
to maintain a hematocrit of >28% was significantly greater 
in the infants treatment group. After heparin reversal, PRBC 
transfusion was greater in the Infants treatment group (p= 
0.047). But FFP transfusion was greater in the infants con-
trol group (p=0.042) after heparin reversal. There were no 
differences in the transfusion of platelets and autologous 
salvaged blood between the infants control and infants treat-
ment groups, as well as in the total amount of intraoperative 
bleeding after heparin reversal. In total, intraoperative trans-
fusion requirements after heparin reversal were greater in 
the infant treatment group. After excluding FFP in the pump 
Table 2-2. Surgical Procedures Performed in Children
Surgical procedure Control Treatment
ASD repair 2 (6.1)    3 (8.9)
VSD repair   5 (15.2)      5 (14.8)
VSD+ASD repair 1 (3.1)
ECD total correction 1 (3.1) 1 (3)
DORV total correction 1 (3)
TOF total correction, primary 1 (3.1)
TOF total correction, following BT shunt 1 (3.1)
Glenn’s shunt 1 (3.1)    2 (5.9)
Fontan op. following Glenn’s shunt   5 (15.2) 1 (3)
Rastelli’s op, primary 1 (3.1)    2 (5.9)
Rastelli’s op, revision 2 (6.1) 1 (3)
RVOT enlargement, primary 1 (3)
RVOT enlargement, revision 1 (3.1)
PVR for PI following RVOT enlargement   6 (18.2)      9 (26.5)
Mitral valve repair for MR 1 (3.1)
MVR, revision 2 (6.1)    2 (5.9)
AVR, revision    2 (5.9)
Subaortic AS repair 1 (3.1)
Residual CoA repair 1 (3.1)
Bentall op 1 (3)
LV aneurysm repair 1 (3)
Pulmonary venous stenosis repair 1 (3.1) 1 (3)
Residual PAPVR repair 1 (3)
VSD, ventricular septal defect; ASD, atrial septal defect; ECD, endocardial 
cushion defect; DORV, double outlet right ventricle; TOF, tetralogy of Fal-
lot; BT shunt, Blalock-Taussig shunt; RVOT, right ventricular outflow tract; 
PVR, pulmonary valve replacement; PI, pulmonary insufficiency; MR, mitral 
regurgitation; MVR, mitral valve replacement; AVR, aortic valve replace-
ment; AS, aortic stenosis; CoA, coarctation of aorta; LV, left ventricle; 
PAPVR, partial anomalous pulmonary venous return.  
Data are presented as numbers of patients (percent). 
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treatment groups of infants and children. After heparin re-
versal, however, significantly greater transfusions of FFP 
were needed intraoperatively in the control groups of in-
fants and children. Unlike in children, overall intraoperative 
transfusion requirements were significantly greater in the 
infants treatment group. The amount of FFP included in 
pump priming presumably made such a difference, because 
transfusion requirement excluding FFP in pump priming 
was comparable between the infants control and infants 
treatment groups. Of the transfusion requirements in the 
significantly less reduced than those in the control groups 
of infants and children. This difference could be attributed 
to the inclusion of FFP in pump priming, as previous inves-
tigations had demonstrated.9,10 
To maintain a target Hct of 28%, significantly more 
PRBCs were added into the CPB circuit in the infant treat-
ment group, which resulted in significantly higher, but clini-
cally acceptable Hb/Hct measurements immediately after 
heparin reversal, compared to the infant control group. Rea-
sonably, more FFP was included into pump prime in the 
Table 3-2. Activated Clotting Time (ACT) Data of Infants and Children*
Infants Children
Control Treatment p value Control Treatment p value
Before incision 137.3±12.4 132.5±17.2 0.25 133.6±13.2 136.2±13.4 0.421
After protamine 148.5 (140.3, 161.8) 134 (122, 143)   0.003 136.2±19.2 133.1±16.6 0.487
*ACT data are presented as mean±SD or median (interquartile range), as appropriate. Before incision, data measured before skin incision. After prot-
amine, data measured after heparin reversal with protamine.
Table 3-1. Hematologic Data of Infants and Children*
Infants Children
Control Treatment p value Control Treatment p value
Hb, g/dL
    Before surgery  11.1±1.6 11.3±1.6 0.628    13 (12.2, 15.7) 13.4 (12.2, 14.5) 0.767
    After protamine  11.7±1.4 12.7±1.4 0.007  10 (9.4, 11.4) 9.7 (8.8, 11.1) 0.523
    ICU 24 hrs  11.8±2.1 11.9±1.9 0.900 11.6 (10.2, 13) 11.4 (10.3, 12.2) 0.510
Hct, %
    Before surgery  33.5±4.7 34.1±4.7 0.672 38.9 (36.8, 45.4) 39.9 (36.5, 43.2) 0.835
    After protamine 33.9±4 36.7±4 0.013 29.5 (27.2, 32.7) 28.6 (26.1, 32.2) 0.692
    ICU 24 hrs  34.6±6.3 34.8±5.9 0.909 33.3 (30.6, 38.4) 33.6 (30.3, 35.8) 0.634
Platelet, 103/µL
    Before surgery 473.5±158   499.8±172.6 0.561 297.5±59.5 286.2±96.5 0.568
    After protamine       96±44.6    100±39.2 0.728 114.2±30.4 117.5±45.9 0.735
    ICU 24 hrs 133.5 (109.5, 173) 144.5 (115, 180.3) 0.634   138 (107.5, 186) 146 (98, 189.5) 0.923
PT (sec)
    Before surgery   11.4 (10.7, 12.3)  11.7 (10.8, 12.7) 0.597 11.8 (11.3, 12.9) 12.1 (11.3, 12.8) 0.715
    ICU 24 hrs   14.8 (13.7, 16.6)  15.3 (14, 16.1) 0.450    15±1.9    15±1.7 0.967
PT (INR)
    Before surgery 1 (0.9, 1)   1 (0.9, 1.1) 0.585 1 (1, 1.1)  1 (0.9, 1.1) 0.633
    ICU 24 hrs 1.3 (1.2, 1.4) 1.3 (1.2, 1.4) 0.463 1.3 (1.1, 1.4) 1.3 (1.2, 1.4) 0.846
aPTT (sec)
    Before surgery     34±5.2 34.9±3.9 0.486 32.9 (31.1, 36.5) 34.3 (31.4, 41.3) 0.262
    ICU 24 hrs      39 (34.7, 47.4)  34.4 (32.4, 42.5) 0.159 32.5 (29.4, 34.8) 31.8 (29.5, 33.8) 0.590
Fibrinogen, mg/dL
    Before surgery 236.5 (184.5, 283.3)       240 (204.5, 260.5) 0.852 269.6±57.8 276.2±51.3 0.628
    After protamine  112.9±29.5    170±42.2 <0.001      136 (116.3, 158.3)      154 (138.8, 193.3) 0.001
    ICU 24 hrs  315.3±78.7 309.7±88.8 0.817 322.3±80.3 342.6±75.1 0.309
Hb, hemoglobin; Hct, hematocrit; PT, prothrombin time; aPTT, activated partial thromboplastin time; INR, international normalization ratio; ICU, intensive 
care unit.
*Hematologic data are presented as mean±SD or median (interquartile range), as appropriate. Before surgery, data from preoperative workup. After prot-
amine, data measured after heparin reversal with protamine, ICU 24 h, data measured at 24 h of ICU stay. 
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resulted in comparable intraoperative bleeding and chest 
tube drainage in the ICU between the control and treatment 
groups of infants and children. We could not, however, con-
firm this within the scope of analyses in this study. 
Although coagulation profiles were evaluated only with 
blood cell counts and/or fibrinogen level, inclusion of FFP 
in pump priming was previously evaluated in neonates (<8-
10 kg) undergoing congenital heart surgery with the goal of 
determining the effects on transfusion and blood loss.9,10 
These previous studies demonstrated that the use of FFP in 
ICU, total amounts were numerically greater in the control 
groups of infants and children, but without statistical signif-
icances. Most of the differences in the transfusion require-
ments in the ICU in infants may be attributed to the greater 
requirement for FFP in the control group. After all, for pa-
tients in control groups, more FFP might be given after hep-
arin reversal in the ICU and intraoperatively in infants and 
children, respectively. This means that FFP transfusion was 
done as a part of the postoperative hemostatic management 
at the discretion of the assigned physician, which may have 
Table 4-1. ROTEM Data, Measured in Infants*
INTEM EXTEM FIBTEM
Control Treatment p value Control Treatment p value Control Treatment p value
CT (sec)
    Before incision
248.5 
(164.3, 304.3)
353 
(194, 436)
0.181
57 
(41.8, 90)
54 
(42, 92)
0.942
    After protamine   461.3±197.9 431.1±208 0.663
97.5 
(71, 129)
80 
(68.5, 112)
0.356
    ICU 24 hrs
319 
(208.8, 421.3)
278 
(204, 401.5)
0.738
  75.5 
(61.8, 99.5)
53 
(43, 87.5)
0.108
A10 (mm)
    Before incision 56.2±7.4  55.1±8.6 0.670
58 
(53.8, 60.5)
57 
(53, 61.5)
0.980
11 
(9, 13.3)
10 
(8, 16)
0.427
    After protamine 24.1±5.8  30.9±6.1 0.002
31 
(23.8, 32.3)
40 
(32.5, 42)
0.001
3 
(3, 4)
7 
(5.5, 8)
<0.001
    ICU 24 hrs   42.7±10.1  47.2±7.1 0.138
47 
(39.8, 52)
50 
(40.5, 54)
0.701    11±3.6 12.1±4.5 0.424
CFT (sec)
    Before incision
66 
(54.8, 105.5)
84 
(60.5, 120.5)
0.400
74 
(60.8, 83.8)
62 
(51, 80)
0.298
    After protamine
439 
(336.5, 546)
267 
(199.5, 343.5)
0.009
262.5 
(227, 419.3)
164 
(135.5, 243.5)
0.002
    ICU 24 hrs
142.5 
(102.3, 215.3)
118 
(92, 149)
0.204
128.5 
(92.3, 163.8)
109 
(91, 174)
0.726
MCF (mm)
    Before incision
65 
(61, 67)
64 
(58, 67.5)
0.762   61±4.2 61.5±7.3 0.793
11.5 
(10, 15)
11 
(9.5, 19.5)
0.312
    After protamine 34.1±6.7  41.1±6.2 0.003 37.3±5.2 45.9±6.3 <0.001
4 
(3, 4)
7 
(6, 9)
<0.001
    ICU 24 hrs
54.5 
(47, 58)
56 
(52, 58)
0.329
54.5 
(49, 59)
56 
(48, 60)
0.954 12.1±4 13.6±5.4 0.341
α (°)
    Before incision
76.5 
(69.3, 79.3)
73 
(67.5, 77.5)
0.446
75 
(73.3, 78)
77 
(74, 79.5)
0.406
    After protamine   39.4±10.3   48.5±11.4 0.019 47.2±9.8 56.6±12.8 0.020
    ICU 24 hrs
64.5 
(54.3, 70.3)
67 
(61.5, 72.5)
0.268
66.5 
(61.5, 72.3)
71 
(61.5, 73.5)
0.409
CT, clotting time; A10, amplitude at 10 min; CFT, clot formation time; α, α-angle; MCF, maximum clot firmness; ICU, intensive care unit.
*Rotational thromboelastogram (ROTEM) data are presented as mean±SD or median (interquartile range), as appropriate. INTEM, EXTEM and FIBTEM: 
ROTEM measurements of intrinsic pathway, extrinsic pathway and fibrinogen activity, respectively. Before incision: data measured before skin incision. 
After protamine: data measured after heparin reversal with protamine, ICU 24 h: data measured at 24 h of ICU stay. 
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including intrinsic and extrinsic pathways and fibrinogen 
activity. Additionally, it has been shown that ROTEM is 
able to identify post-bypass coagulation abnormalities more 
quickly and with higher specificity, compared to standard 
coagulation tests.15,16
In infants, ACT measurements were nearly restored to the 
original levels measured before skin incision in both control 
and treatment groups. With respect to ROTEM measure-
ments, however, clot initiation was delayed because CT in 
INTEM measurements was prolonged to nearly twice the 
pump priming only augmented post-CPB fibrinogen level, 
and did not reduce transfusion requirements and/or chest 
tube drainage, similar to the results of this study using hema-
tologic assays. Thus, it is important to adopt a certain method 
to evaluate the coagulation profiles functionally. One study 
performed the functional evaluations with thromboelastogra-
phy (TEG) in pediatric patients after CPB, but found no dif-
ferences in TEG parameters between groups.9 In this study, 
however, ROTEM is a reagent-assisted method with the 
ability to examine all aspects of the coagulation pathways, 
Table 4-2. ROTEM Data Measured in Children*
INTEM EXTEM FIBTEM
Control Treatment p value Control Treatment p value Control Treatment p value
CT (sec)
    Before incision
233.5 
(189.5, 368.5)
232.5 
(184.8, 348.8)
0.978
66 
(43, 84)
76 
(62.8, 90.5)
0.139
    After protamine
323 
(208.3, 427.8)
318 
(228.8, 540.8)
0.552
107.5 
(70, 161.8)
81 
(67.8, 114.3)
0.131
    ICU 24 hrs
218 
(184, 394)
244.5 
(183.8, 314.5)
0.703
79 
(69, 110)
66 
(48.5, 86)
0.089
A10 (mm)
    Before incision
49 
(41.3, 53)
48 
(43, 54.3)
0.764
52 
(48, 54)
50 
(46, 55)
0.616
10 
(8, 11)
10 
(8, 12.5)
0.738
    After protamine 30.5±5.4 33±8 0.242 33.5±6.7    37.8±10.8 0.109
4.5 
(3, 5.8)
7 
(4, 9.3)
0.010
    ICU 24 hrs   42.5±11.5   46.9±12.2 0.240 49.8±7.8 48.9±14 0.786
14 
(10.5, 16.5)
16.5 
(12.3, 20.8)
0.081
CFT (sec)
    Before incision
96.5 
(83.3, 154.8)
100.5 
(71, 153.5)
0.781
91 
(78, 106)
88.5 
(78.8, 121)
0.657
    After protamine
250.5 
(210.5, 320.3)
259.5 
(163.8, 355)
0.802
198 
(168.3, 315.8)
171 
(109, 269.5)
0.044
    ICU 24 hrs
116 
(91.5, 201)
107 
(87, 168)
0.218
112 
(95, 158.5)
104 
(88, 150)
0.337
MCF (mm)
    Before incision 56.6±6 56.8±7.1 0.904
56 
(54, 60)
55.5 
(52.5, 59)
0.445
11 
(9, 12.8)
11.5 
(10, 14.3)
0.376
    After protamine 40.8±5.4 42.9±7 0.256 42.6±6.5    45.7±11.2 0.245
5 
(4, 6)
8 
(4.8, 10)
0.011
    ICU 24 hrs 52±9      55±11.2 0.357
57 
(53, 61)
58 
(52.5, 62.8)
0.583
15 
(12, 19)
19.5 
(13.5, 24.8)
0.048
α (°)
    Before incision
72 
(62, 73)
70 
(61.3, 76)
1.000
72 
(69, 74)
71.5 
(66, 74)
0.647
    After protamine 50.4±9.2   50.8±12.6 0.913
55.5 
(45, 58.8)
60 
(46.5, 68)
0.028
    ICU 24 hrs
67 
(55.5, 72)
69 
(60, 73.8)
0.321
69 
(62, 73)
70 
(64, 74)
0.472
CT, clotting time; A10, amplitude at 10 min; CFT, clot formation time; α, α-angle; MCF, maximum clot firmness; ICU, intensive care unit.
*Rotational thromboelastogram (ROTEM) data are presented as mean±SD or median (interquartile range), as appropriate. INTEM, EXTEM and FIBTEM: 
ROTEM measurements of intrinsic pathway, extrinsic pathway and fibrinogen activity, respectively. Before incision: data measured before skin incision. 
After protamine: data measured after heparin reversal with protamine, ICU 24 h: data measured at 24 h of ICU stay.  
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platelet inhibition reagent. Moreover, platelet count was simi-
larly reduced in both control and treatment groups after 
heparin reversal, but the fibrinogen level was significantly 
less reduced in the treatment group. Prevention of fibrino-
gen reduction in the treatment group may explain why clot 
firmness was significantly less affected by a dilution coagu-
lopathy. Previously, it was demonstrated that fibrinogen 
level was important for clot strength especially in the set-
ting of platelet deficiency.17
In children, a similar pattern of dilutional coagulopathy to 
that of infants, delayed clot initiation and formation, and re-
duced clot firmness after heparin reversal. In contrast, there 
were no significant differences between the children control 
and children treatment groups in the coagulation profile of 
the intrinsic pathway, evaluated with INTEM measure-
ments. In the consideration of less elevated CT in INTEM 
measurements, an equal restoration of ACT and much less 
reduced platelet count in both control and treatment groups 
upper normal limit after heparin reversal in both control 
and treatment groups, which is considered to be a residual 
effect of heparin. Clot formation was also delayed after hep-
arin reversal because of prolonged CFT and reduced α-angle 
in both control and treatment groups. FFP in pump priming 
significantly improved delayed clot formation, which was 
shown by findings of significantly less altered CFT and 
α-angle in the treatment group. Clot firmness was reduced 
in both control and treatment groups after heparin reversal. 
However, the use of FFP in pump priming also significantly 
improved clot firmness in the infants treatment group, as 
evidenced by less reduced TEG parameters reflecting clot 
firmness, A10 and MCF. Reduced clot firmness demon-
strated in both INTEM and EXTEM measurements could 
be attributed to platelet or fibrinogen deficiency. A reduc-
tion in clot firmness shown in this study was primarily at-
tributed to fibrinogen deficiency because clot firmness was 
also measured to be reduced in FIBTEM, which utilizes 
Table 5-1. Intraoperative Bleeding and Transfusion Requirements in Infants and Children*
Infants Children
Control Treatment p value Control Treatment p value
Pump priming
    FFP (mL)      0 (0, 0)  150 (150, 150) <0.001      0 (0, 0)  300 (150, 300) <0.001
    PRBC (mL)  125 (125, 125)  125 (125, 125) 1.000  250 (0, 250)  125 (0, 250) 0.203
    Additional PRBC into CPB circuit (mL)  125 (125, 125)  125 (125, 250) 0.002      0 (0, 250)      0 (0, 125) 0.742
After heparin reversal
    Bleeding (mL/kg) 12.2 (9.6, 18.3) 12.3 (7.8, 16.7) 0.677    10 (6.4, 16.1)    10 (6, 13.1) 0.893
    Transfusion
        PRBC (mL)   2.5 (0, 37.5)    40 (0, 70) 0.047  125 (0, 412.5)      5 (0, 375) 0.302
        FFP (mL)      0 (0, 43.1)      0 (0, 0) 0.042  150 (0, 300)      0 (0, 11.3) 0.002
        Platelet (mL)      0 (0, 0)      0 (0, 0) 0.342      0 (0, 0)      0 (0, 0) 0.717
        Salvaged blood (mL)    15 (0, 53.8)    25 (0, 32.5) 0.946  230 (60, 415)  100 (30, 505) 0.368
    Total transfusion requirements (mL/kg) 61.7 (47.4, 83.6) 94.2 (76.1, 128.4) 0.001 34.4 (20.1, 65.7) 32.4 (20.2, 52.8) 0.857
    Total transfusion requirements excluding 
      FFP in pump priming (mL/kg)
61.7 (47.4, 83.6)    64 (52.5, 86.3) 0.497 34.4 (20.1, 65.7) 21.8 (12.9, 41.3) 0.060
FFP, fresh frozen plasma; PRBC, packed red blood cell; CPB, cardiopulmonary bypass. 
*Data on intraoperative bleeding and transfusion requirements are presented as median (interquartile range).
Table 5-2. Bleeding and Transfusion Requirements in Infants and Children during 24 h in the ICU*
Infants Children
Control Treatment p value Control Treatment p value
Total chest tube drainage (mL/kg)    10 (6.9, 22.5) 10.3 (7.4, 17.3) 0.956 12.2 (6.9, 28.5) 11.5 (6.4, 19.1) 0.495
Transfusion
    PRBC (mL) 12.5 (0, 66.8)      5 (0, 42.5) 0.567      0 (0, 125)      0 (0, 120) 0.975
    FFP (mL) 32.5 (0, 50)      0 (0, 38.8) 0.102      0 (0, 157)      0 (0, 242.5) 0.598
    Platelet (mL)      0 (0, 36)      0 (0, 31.3) 0.944      0 (0, 30)      0 (0, 20) 0.955
    Pump blood (mL)      0 (0, 18.8)      0 (0, 3.8) 0.386      0 (0, 15)      0 (0, 145) 0.718
Total transfusion requirement (mL/kg) 15.9 (4.6, 33.5)   7.9 (0.4, 14.4) 0.065    10 (0, 14.6)   6.3 (1.9, 15.3) 0.863
PRBC, packed red blood cell; FFP, fresh frozen plasma; ICU, intensive care unit. 
*Data on bleeding and transfusion requirements during 24 h in the ICU are presented as median (interquartile range).
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tion of ACT to the preoperative value was not shown to 
guarantee full recovery of clot initiation, as ROTEM mea-
surements remained elongated. Actually, ROTEM was dem-
onstrated to be useful to exclude residual heparin effects on 
elongated ACT after CPB in a previous pilot study.18 In this 
study, functional evaluation of blood coagulation with 
ROTEM measurements provided a more detailed picture of 
postoperative hemostasis, including more augmented ef-
fects of residual heparin in infants, and clot formation and 
clot strength measurements that were less affected by dilu-
tional hypofibrinogenemia with FFP in pump priming.
There are some limitations in this study. First, reference 
values for qualitative and quantitative methods of blood co-
agulation, especially ROTEM measurements, have not 
been specified in a pediatric population. Therefore, adult 
values had to be used in this study.19 Second, plasma oncotic 
pressures of pump priming were assumed to be comparable 
between the control and treatment groups by reducing the 
amount of crystalloid included in pump priming to obtain a 
volume difference between 20% albumin and FFP. Consid-
ering that 20% albumin has three times the level of oncotic 
pressure with the one third of volume of FFP, it would be 
acceptable clinically. Additionally, it was previously report-
ed that oncotic pressure of pump priming did not affect 
postoperative findings including transfusion requirements 
and postoperative bleeding.20 Third, to confirm the residual 
effects of heparin, it is better to use HEPTEM of ROTEM 
measurements, which additionally uses heparinase. Howev-
er, this was not commercially available when this study was 
being conducted. Most of all, most of transfusions were 
done based on empirical decision of the assigned physician 
due to lack of consensus on transfusion threshold in pediat-
ric patients after cardiac surgery. Use of predetermined 
transfusion guidelines based on point-of-care tests, such as 
ROTEM, would allow for more effective means to predict 
transfusion requirements, as in other investigations on the 
use of ROTEM measurements for determining transfusion 
requirements.21
In conclusion, inclusion of FFP in pump priming for con-
genital heart surgery in infants and children was shown to 
improve hemodilution-related coagulation dysfunction im-
mediately after weaning from CPB and heparin reversal. 
However, beneficial effects were not shown to be continued 
until 24 h in the ICU, and clinical benefits were not clearly 
evident. To evaluate clinical and functional benefits of FFP 
in pump priming, large, randomized investigations with 
risk stratification are necessary in the future. Furthermore, it 
after protamine administration, children undergoing congen-
ital heart surgery were shown to be less affected by residual 
heparin and hemodilution, compared to infants. As previous-
ly demonstrated, post-CPB coagulopathy was shown to be 
dependent on age.11-13 For extrinsic pathway measurements, 
clot formation was shown to be significantly less delayed in 
the children treatment group, evidenced by significantly less 
altered CFT and α-angle after heparin reversal. Fibrinogen 
activity, evaluated by FIBTEM measurements, was signifi-
cantly less affected in the children treatment group, demon-
strated by significantly less reduced A10 and MCF values. 
As in infants, reduced clot firmness in the children control 
group could be attributed to fibrinogen deficiency, as param-
eters reflecting clot firmness were reduced in all ROTEM 
measurements after heparin reversal. In the children treat-
ment group, however, clot firmness measured with FIBTEM 
was reduced from baseline value, but was nearly within the 
normal range. Furthermore, fibrinogen level was significant-
ly less reduced than that in the children control group while 
platelet count between the control and treatment groups 
were comparable. These results suggest that the use of FFP 
in pump priming has a beneficial effect on clot firmness af-
ter heparin reversal in children undergoing cardiac surgery 
with CPB. 
Beneficial effects of FFP in pump priming were not sus-
tained until 24 h postoperatively, as evidenced by the lack 
of significant differences in hematologic and ROTEM data 
recorded at 24 h in the ICU in both infants and children. 
Furthermore, clinical benefits to reduce transfusion require-
ments and/or postoperative bleeding were not clearly dem-
onstrated. As mentioned above, FFP transfusion in the con-
trol groups of infants and children were done immediately 
after heparin reversal and during ICU stay for postoperative 
hemostasis. As reported previously, a certain positive clini-
cal effect would have been found if the patients were cate-
gorized with the complexity of the surgery or cyanosis.9 In 
fact, however, the complexity of the surgery could be a sub-
jective measurement made by the surgeon and the propor-
tion of cyanotic patients was too small to be separately ana-
lyzed in this study.
In this study, we found that commonly used clinical pa-
rameters of coagulation profiles have certain limitations. 
Important components of the coagulation pathway, includ-
ing platelet count and fibrinogen level, were shown to be 
quantitatively reduced in spite of sufficient restoration of 
Hb/Hct measurements by means of free water removal, 
such as modified ultrafiltration. Likewise, sufficient restora-
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gers AJ. Relevance of colloid oncotic pressure regulation during 
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is necessary to adopt predetermined, clinical transfusion 
guidelines based on point-of-care tests, which can provide 
information not only on the quantitative aspects, but also on 
the qualitative aspects of coagulation profiles. 
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